Literature DB >> 29018050

Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier.

Cody J Peer1, Cindy H Chau2, William D Figg3,2.   

Abstract

Determining the penetration of drugs across the blood-brain barrier is a significant challenge in central nervous system drug development. The use of a mechanistic physiologically based pharmacokinetic model can predict drug exposures in the brain without needing in situ drug measurements. Clin Cancer Res; 23(24); 7437-9. ©2017 AACRSee related article by Li et al., p. 7454. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29018050      PMCID： PMC5732885          DOI： 10.1158/1078-0432.CCR-17-2741

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  7 in total

Review 1.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

2.  Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data.

Authors:  Lu Gaohua; Sibylle Neuhoff; Trevor N Johnson; Amin Rostami-Hodjegan; Masoud Jamei
Journal:  Drug Metab Pharmacokinet       Date:  2016-04-04       Impact factor: 3.614

3.  Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Authors:  Jing Li; Jianmei Wu; Xun Bao; Norissa Honea; Youming Xie; Seongho Kim; Alex Sparreboom; Nader Sanai
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

4.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

5.  The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.

Authors:  Jenny L Pokorny; David Calligaris; Shiv K Gupta; Dennis O Iyekegbe; Dustin Mueller; Katrina K Bakken; Brett L Carlson; Mark A Schroeder; Debra L Evans; Zhenkun Lou; Paul A Decker; Jeanette E Eckel-Passow; Vincenzo Pucci; Bennett Ma; Stuart D Shumway; William F Elmquist; Nathalie Y R Agar; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

6.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer.

Authors:  L E Gerweck; K Seetharaman
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy.

Authors:  G R Martin; R K Jain
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.